INSIDER
OverviewFollow the MoneyDaily BriefLiveCongressDirectoryCorporate InsidersPlanned Sales & StakesGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
Alerts on Telegram

Congress trades and big insider sales, sent the day they're filed. Free.

Open in Telegram
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

Robinhood Chain…
OverviewFollow the MoneyDaily BriefLiveCongressDirectoryCorporate InsidersPlanned Sales & StakesGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyTelegram alerts
OverviewFollow the MoneyDaily BriefLiveCongressDirectoryCorporate InsidersPlanned Sales & StakesGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
Alerts on Telegram

Congress trades and big insider sales, sent the day they're filed. Free.

Open in Telegram
OverviewFollow the MoneyDaily BriefLiveCongressDirectoryCorporate InsidersPlanned Sales & StakesGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyTelegram alerts
03 · Corporate insiders

Form 4 filings

Officers, directors and 10% owners must report trades within two business days on SEC Form 4. INSIDER parses each filing's XML from EDGAR. By default only discretionary open-market purchases and sales are shown; grants, option exercises and tax withholding are one click away.

Form 4 transactions

Cluster activity · 60d

Most active filers

Companies with the most Form 4 filings
Data sources
SEC Form 44h ago
House PTR4h ago
SEC 13F4h ago
Robinhood Chain4h ago

Most active filers · 30d

  1. 01Kurtz George0B / 215S215 trades$52.62M
  2. 02SPSaba Capital Management, L.P.77B / 19S · 11 late96 trades$25.89M
  3. 03FWFogarty Patrick W0B / 90S90 trades$362K
  4. 04SJSheena Jonathan0B / 57S57 trades$3.61M
  5. 05ATAdair Kathleen Theresa52B / 0S · 52 late52 trades$18K
  6. 06AJAllaire Jeremy0B / 50S50 trades$4.26M
  7. 07Wilhelmsen Arne Alexander0B / 47S47 trades$241.96M
  8. 08SLSpeiser Michael L0B / 35S35 trades$14.00M
  9. 09RARothblatt Martine A0B / 33S33 trades$5.50M
  10. 10RJRubinstein Julie0B / 32S32 trades$5.48M

Cluster activity · 60d

  1. BUYTSMTAIWAN SEMICONDUCTOR MANUFACTURING CO LTDNov 5 – Nov 1732 insiders$917K
  2. SELLDRDDRDGOLD LTDOct 27 – Oct 2710 insiders$1.23M
  3. BUYMTDRMatador Resources CoNov 5 – Nov 109 insiders$765K
  4. SELLMSIMotorola Solutions, Inc.Nov 6 – Nov 108 insiders$40.91M
  5. SELLFFIVF5, INC.Nov 3 – Nov 58 insiders$8.37M
  6. SELLIBEXIBEX LtdNov 9 – Nov 167 insiders$3.36M
  7. SELLMGNIMAGNITE, INC.Nov 5 – Nov 127 insiders$2.27M
  8. SELLSYMSymbotic Inc.Oct 26 – Nov 27 insiders$1.98M

Form 4 transactions

71,797 records
Side
allbuysell
Score
any≥ 30≥ 50≥ 70
Sort
Newest disclosedNewest executedInsider ScoreValue
Include
grants & admin
ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
23
FJ
Fitzgerald Kevin JosephCSO & EVP, Head of Research
ALNYALNYLAM PHARMACEUTICALS, INC.
Open-market sale · 10b5-1 plan
SELL$80K
220 sh
Jan 12, 2026
Page 1463 of 1795
← PrevNext →
Jan 14, 2026
traded Jan 12, 2026
+2d
SEC Form 4

Evidence

23
FJ
Fitzgerald Kevin JosephCSO & EVP, Head of Research
ALNYALNYLAM PHARMACEUTICALS, INC.
Open-market sale · 10b5-1 plan
SELL$73K
199 sh
Jan 12, 2026Jan 14, 2026
traded Jan 12, 2026
+2dSEC Form 4

Evidence

23
JC
Jay ColleenDirector
COOCOOPER COMPANIES, INC.
Option exercise
M$278K
7,064 sh
Jan 12, 2026Jan 14, 2026
traded Jan 12, 2026
+2dSEC Form 4

Evidence

23
DK
DeHoff KateSee Remarks
JOBYJoby Aviation, Inc.
Open-market sale · 10b5-1 plan
SELL$105K
7,092 sh
Jan 13, 2026Jan 14, 2026
traded Jan 13, 2026
+1dSEC Form 4

Evidence

22
GS
Gatzke Carla SSecretary and VP of Human Reso
DAKTDAKTRONICS INC /SD/
Gift
G—
1,800 sh
Dec 23, 2025Jan 14, 2026
traded Dec 23, 2025
+22dSEC Form 4

Evidence

22
MB
McBee BranninChief Development Officer
CRWVCoreWeave, Inc.
Open-market sale · 10b5-1 plan
SELL$4,740
55 sh
Jan 12, 2026Jan 14, 2026
traded Jan 12, 2026
+2dSEC Form 4

Evidence

22
MB
McBee BranninChief Development Officer
CRWVCoreWeave, Inc.
Open-market sale · 10b5-1 plan
SELL$11K
127 sh
Jan 12, 2026Jan 14, 2026
traded Jan 12, 2026
+2dSEC Form 4

Evidence

22
MB
McBee BranninChief Development Officer
CRWVCoreWeave, Inc.
Open-market sale · 10b5-1 plan
SELL$11K
128 sh
Jan 12, 2026Jan 14, 2026
traded Jan 12, 2026
+2dSEC Form 4

Evidence

22
MB
McBee BranninChief Development Officer
CRWVCoreWeave, Inc.
Open-market sale · 10b5-1 plan
SELL$4,654
54 sh
Jan 12, 2026Jan 14, 2026
traded Jan 12, 2026
+2dSEC Form 4

Evidence

22
MB
McBee BranninChief Development Officer
CRWVCoreWeave, Inc.
Open-market sale · 10b5-1 plan
SELL$14K
164 sh
Jan 12, 2026Jan 14, 2026
traded Jan 12, 2026
+2dSEC Form 4

Evidence

22
KA
Kurtenbach Reece ADirector
DAKTDAKTRONICS INC /SD/
Gift
G—
1,800 sh
Dec 23, 2025Jan 14, 2026
traded Dec 23, 2025
+22dSEC Form 4

Evidence

22
MB
McBee BranninChief Development Officer
CRWVCoreWeave, Inc.
Open-market sale · 10b5-1 plan
SELL$33K
381 sh
Jan 12, 2026Jan 14, 2026
traded Jan 12, 2026
+2dSEC Form 4

Evidence

22
CS
Cutler ScottDirector, President and CEO
HQYHEALTHEQUITY, INC.
Tax withholding
F$1.12M
12.5K sh
Jan 12, 2026Jan 14, 2026
traded Jan 12, 2026
+2dSEC Form 4

Evidence

22
KJ
Kurtenbach Matthew JohnVP of Manufacturing
DAKTDAKTRONICS INC /SD/
Gift
G—
1,800 sh
Dec 23, 2025Jan 14, 2026
traded Dec 23, 2025
+22dSEC Form 4

Evidence

22
MB
McBee BranninChief Development Officer
CRWVCoreWeave, Inc.
Open-market sale · 10b5-1 plan
SELL$42K
482 sh
Jan 12, 2026Jan 14, 2026
traded Jan 12, 2026
+2dSEC Form 4

Evidence

21
CS
Chernylo SofiaCAO
NTSTNETSTREIT Corp.
Option exercise
M—
6,033 sh
Jan 13, 2026Jan 14, 2026
traded Jan 13, 2026
+1dSEC Form 4

Evidence

21
SS
Subotovsky SantiagoDirector
ZMZoom Communications, Inc.
Derivative conversion
C—
1.34M sh
Jan 12, 2026Jan 14, 2026
traded Jan 12, 2026
+2dSEC Form 4

Evidence

21
MB
McBee BranninChief Development Officer
CRWVCoreWeave, Inc.
Open-market sale · 10b5-1 plan
SELL$122K
1,328 sh
Jan 12, 2026Jan 14, 2026
traded Jan 12, 2026
+2dSEC Form 4

Evidence

21
MB
McBee BranninChief Development Officer
CRWVCoreWeave, Inc.
Open-market sale · 10b5-1 plan
SELL$65K
775 sh
Jan 12, 2026Jan 14, 2026
traded Jan 12, 2026
+2dSEC Form 4

Evidence

21
OM
Oelschlager Kristen MChief Operating Officer
CSTLCASTLE BIOSCIENCES INC
Grant or award
A—
9,207 sh
Jan 12, 2026Jan 14, 2026
traded Jan 12, 2026
+2dSEC Form 4

Evidence

21
BR
Brumana RodrigoChief Financial Officer
JOBYJoby Aviation, Inc.
Option exercise
M—
1,221 sh
Jan 12, 2026Jan 14, 2026
traded Jan 12, 2026
+2dSEC Form 4

Evidence

21
SB
Starr Daniel BrianDirector
LKFNLAKELAND FINANCIAL CORP
Grant or award
A$18K
309 sh
Jan 12, 2026Jan 14, 2026
traded Jan 12, 2026
+2dSEC Form 4

Evidence

21
MB
McBee BranninChief Development Officer
CRWVCoreWeave, Inc.
Open-market sale · 10b5-1 plan
SELL$167K
2,105 sh
Jan 12, 2026Jan 14, 2026
traded Jan 12, 2026
+2dSEC Form 4

Evidence

21
MB
McBee BranninChief Development Officer
CRWVCoreWeave, Inc.
Open-market sale · 10b5-1 plan
SELL$75K
868 sh
Jan 12, 2026Jan 14, 2026
traded Jan 12, 2026
+2dSEC Form 4

Evidence

21
Saba Capital Management, L.P.10% Owner
GFNEW GERMANY FUND INC
Open-market sale
SELL$24K
2,000 sh
Jan 13, 2026Jan 14, 2026
traded Jan 13, 2026
+1dSEC Form 4

Evidence

21
SW
Simi Bonny WPresident of Operations
JOBYJoby Aviation, Inc.
Option exercise
M—
3,303 sh
Jan 12, 2026Jan 14, 2026
traded Jan 12, 2026
+2dSEC Form 4

Evidence

21
MB
McBee BranninChief Development Officer
CRWVCoreWeave, Inc.
Open-market sale · 10b5-1 plan
SELL$65K
776 sh
Jan 12, 2026Jan 14, 2026
traded Jan 12, 2026
+2dSEC Form 4

Evidence

21
MB
McBee BranninChief Development Officer
CRWVCoreWeave, Inc.
Open-market sale · 10b5-1 plan
SELL$53K
637 sh
Jan 12, 2026Jan 14, 2026
traded Jan 12, 2026
+2dSEC Form 4

Evidence

21
BJ
Bevirt JoeBenDirector, CEO and Chief Architect, 10% Owner
JOBYJoby Aviation, Inc.
Option exercise
M—
4,371 sh
Jan 12, 2026Jan 14, 2026
traded Jan 12, 2026
+2dSEC Form 4

Evidence

21
MB
McBee BranninChief Development Officer
CRWVCoreWeave, Inc.
Open-market sale · 10b5-1 plan
SELL$75K
869 sh
Jan 12, 2026Jan 14, 2026
traded Jan 12, 2026
+2dSEC Form 4

Evidence

21
SB
Starr Daniel BrianDirector
LKFNLAKELAND FINANCIAL CORP
Grant or award
A—
650 sh
Jan 13, 2026Jan 14, 2026
traded Jan 13, 2026
+1dSEC Form 4

Evidence

21
CS
Chernylo SofiaCAO
NTSTNETSTREIT Corp.
Tax withholding
F$48K
2,694 sh
Jan 13, 2026Jan 14, 2026
traded Jan 13, 2026
+1dSEC Form 4

Evidence

21
MB
McBee BranninChief Development Officer
CRWVCoreWeave, Inc.
Open-market sale · 10b5-1 plan
SELL$84K
986 sh
Jan 12, 2026Jan 14, 2026
traded Jan 12, 2026
+2dSEC Form 4

Evidence

20
FJ
Fitzgerald Kevin JosephCSO & EVP, Head of Research
ALNYALNYLAM PHARMACEUTICALS, INC.
Open-market sale · 10b5-1 plan
SELL$745
2 sh
Jan 12, 2026Jan 14, 2026
traded Jan 12, 2026
+2dSEC Form 4

Evidence

20
FJ
Fitzgerald Kevin JosephCSO & EVP, Head of Research
ALNYALNYLAM PHARMACEUTICALS, INC.
Open-market sale · 10b5-1 plan
SELL$17K
47 sh
Jan 12, 2026Jan 14, 2026
traded Jan 12, 2026
+2dSEC Form 4

Evidence

20
FJ
Fitzgerald Kevin JosephCSO & EVP, Head of Research
ALNYALNYLAM PHARMACEUTICALS, INC.
Open-market sale · 10b5-1 plan
SELL$26K
73 sh
Jan 12, 2026Jan 14, 2026
traded Jan 12, 2026
+2dSEC Form 4

Evidence

20
FJ
Fitzgerald Kevin JosephCSO & EVP, Head of Research
ALNYALNYLAM PHARMACEUTICALS, INC.
Open-market sale · 10b5-1 plan
SELL$34K
96 sh
Jan 12, 2026Jan 14, 2026
traded Jan 12, 2026
+2dSEC Form 4

Evidence

20
FJ
Fitzgerald Kevin JosephCSO & EVP, Head of Research
ALNYALNYLAM PHARMACEUTICALS, INC.
Open-market sale · 10b5-1 plan
SELL$7,137
19 sh
Jan 12, 2026Jan 14, 2026
traded Jan 12, 2026
+2dSEC Form 4

Evidence

20
FJ
Fitzgerald Kevin JosephCSO & EVP, Head of Research
ALNYALNYLAM PHARMACEUTICALS, INC.
Open-market sale · 10b5-1 plan
SELL$15K
41 sh
Jan 12, 2026Jan 14, 2026
traded Jan 12, 2026
+2dSEC Form 4

Evidence

20
FJ
Fitzgerald Kevin JosephCSO & EVP, Head of Research
ALNYALNYLAM PHARMACEUTICALS, INC.
Open-market sale · 10b5-1 plan
SELL$31K
85 sh
Jan 12, 2026Jan 14, 2026
traded Jan 12, 2026
+2dSEC Form 4

Evidence